Distigmine

Summary

Distigmine (CHEMBL1199307) is an approved small-molecule EC 3.1.1.8 (cholinesterase) inhibitor (ATC N07AA03).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N07AA03
• Chemistry: 416.5 Da · C22H32N4O4+2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1199307
Name	Distigmine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3116
ChEBI	CHEBI:80756
ATC	N07AA03
Molecular formula	C22H32N4O4+2
Molecular weight	416.5
InChIKey	AHZBEVXBKNYXPU-UHFFFAOYSA-N

SMILES: C[N+]1=CC=CC(=C1)OC(=O)N(C)CCCCCCN(C)C(=O)OC2=C[N+](=CC=C2)C

IUPAC name: (1-methylpyridin-1-ium-3-yl) N-methyl-N-[6-[methyl-(1-methylpyridin-1-ium-3-yl)oxycarbonylamino]hexyl]carbamate

ChEBI definition: A carbamate ester resulting from the formal condensation of both carboxy groups of hexane-1,6-diylbis(methylcarbamic acid) with the hydroxy group of 3-hydroxy-1-methylpyridinium.

Pharmacological roles (ChEBI): EC 3.1.1.8 (cholinesterase) inhibitor, muscarinic agonist.

Also known as: Distigmine, Distigmine cation, Distigmine ion, DISTIGMINE

Parent form; salt/anhydrous children: CHEMBL1098285

Patent coverage: 5 distinct patent families (7 SureChEMBL compound mentions), from 3 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).